Alliance Global Partners analyst Aaron Grey raised the firm’s price target on Trulieve Cannabis to C$20 from C$16 and keeps a Buy rating on the shares. The company reported a “strong beat” in Q4, the analyst tells investors in a research note. The firm says its thesis for Trulieve remains intact with the company embedding the benefits of its Jeffco facility, launch of its loyalty program nationwide, along with a notable potential catalyst from adult-use sales legalization in Florida.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TCNNF:
- Trulieve Reports Fourth Quarter and Full Year 2023 Results Highlighting Year End Momentum and Cash Generation
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Rising High: Exclusive talk with cannabis market research firm BDSA
- Rising High: Exclusive talk with house of brands Carma HoldCo
- Rising High: Exclusive talk with drug manufacturer Optimi Health
